Metabolic dysfunction–associated steatohepatitis (MASH) is a severe form of liver disease
that poses a global health threat because of its potential to progress to advanced fibrosis …

Tight junctions (TJs) are intercellular protein complexes that preserve tissue homeostasis
and integrity through the control of paracellular permeability and cell polarity. Recent …

Therapy resistance is the primary problem in treating late-stage colorectal cancer (CRC).
Claudins are frequently dysregulated in cancer, and several are being investigated as novel …

Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as non-
alcoholic fatty liver disease) is a leading cause of chronic liver disease worldwide. MASLD …

Hepatocellular carcinoma (HCC) has a high incidence and dismal prognosis, making it a
significant global health burden. To change this, the development of new therapeutic …

Adhesion after tendon injury, which can result in limb movement disorders, is a common
clinical complication; however, effective treatment methods are lacking. Hyaluronic acid …

In the last decade tight junction proteins exposed at the surface of liver or cancer cells have
been uncovered as mediators of liver disease biology: Claudin-1 and Occludin are host …

Cancer therapy-related cardiac dysfunction (CTRCD), which commonly includes left
ventricular dysfunction and heart failure, is the main adverse effect of anticancer therapy. In …

Background & Aims Liver fibrosis is the major driver of hepatocellular carcinoma and liver
disease-related death. Approved antifibrotic therapies are absent and compounds in …

The advent of molecular profiling and the generalization of next generation sequencing in
oncology has enabled the identification of patients who could benefit from targeted agents …